Takeda

Takeda Pharmaceutical Company Limited is Japan's largest pharmaceutical company and a top-20 global biopharma, founded in 1781, dual-headquartered in Tokyo and Osaka, with five core therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies (PDTs). Following its 2019 acquisition of Shire it gained a leading position in rare diseases and plasma therapies. Its manufacturing footprint spans ~80 countries and includes a global plasma network of eight facilities plus solid-dose, biologics/cell-therapy, and fill-finish sites. For AGD purposes the relevant signal is its parenteral and combination-product manufacturing (vials, prefilled syringes, autoinjectors, plasma fill-finish) plus an active, publicly stated automation/robotics agenda across multiple plants. Note: Takeda is the END USER/manufacturer, not a robotics vendor; opportunity centers on contact-rich tasks inside its GMP sterile-fill and device-assembly lines.